11 October, 2013
The likelihood of complications from long-term central venous access devices can be greatly reduced by health professionals being aware of their causes Abstract Patient assessment and the appropriate management of long-term central venous access devices are essential to diminishing the potential for complications. When complications do occur, they tend to be the consequence of a series of events. Recognising problems at an early stage means they can be addressed sooner and improves the chances of resolving them without any long-term consequences. Gabriel J (2013) Venous access devices part 2: preventing and managing complications of CVADs. Nursing Times; 109: 40, 20-23. Author:Â Janice Gabriel is strategic clinical networks manager at NHS England (Wessex), Southampton. This article has been double-blind peer reviewed Scroll down to read the article or download a print-friendly PDF, including any tables and figures
To continue reading this clinical article please log in or subscribe.
Already have an account, click here to sign in
1. LeVasseur N., Stober C., Daigle K. View of Optimizing vascular access for patients receiving intravenous systemic therapy for early-stage breast cancer—A survey of oncology nurses and physicians. [(accessed on 26 September 2020)];Curr. Oncol. 2018 25:298–304. Available online: //www.current-oncology.com/index.php/oncology/article/view/3903/2847 [PMC free article] [PubMed] [Google Scholar]
2. Ho C., Spry C. Central Venous Access Devices (CVADs) and Peripherally Inserted Central Catheters (PICCs) for Adult and Pediatric Patients: A Review of Clinical Effectiveness and Safety. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. [(accessed on 26 September 2020)]; Available online: //www.ncbi.nlm.nih.gov/books/NBK470804/
3. Gallieni M., Pittiruti M., Biffi R. Vascular access in oncology patients. CA Cancer J. Clin. 2008;58:323–346. doi: 10.3322/CA.2008.0015. [PubMed] [CrossRef] [Google Scholar]
4. Assessment and Device Selection for Vascular Access Registered Nursing Association of Ontario. [(accessed on 4 October 2020)];2004 Available online: //rnao.ca/bpg/guidelines/assessment-and-device-selection-vascular-access
5. Schiffer C.A., Mangu P.B., Wade J.C., Camp-Sorrell D., Cope D.G., El-Rayes B.F., Gorman M., Ligibel J., Mansfield P., Levine M. Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 2013;31:1357–1370. doi: 10.1200/JCO.2012.45.5733. [PubMed] [CrossRef] [Google Scholar]
6. Patel G.S., Jain K., Kumar R., Strickland A.H., Pellegrini L., Slavotinek J., Eaton M., McLeay W., Price T., Ly M., et al. Comparison of peripherally inserted central venous catheters (PICC) versus subcutaneously implanted port-chamber catheters by complication and cost for patients receiving chemotherapy for non-haematological malignancies. Support Care Cancer. 2014;22:121–128. doi: 10.1007/s00520-013-1941-1. [PubMed] [CrossRef] [Google Scholar]
7. Morano S.G., Latagliata R., Girmenia C., Massaro F., Berneschi P., Guerriero A., Giampaoletti M., Sammarco A., Annechini G., Fama A., et al. Catheter-associated bloodstream infections and thrombotic risk in hematologic patients with peripherally inserted central catheters (PICC) Support Care Cancer. 2015;23:3289–3295. doi: 10.1007/s00520-015-2740-7. [PubMed] [CrossRef] [Google Scholar]
8. Khorana A.A., Kuderer N.M., Culakova E., Lyman G.H., Francis C.W. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;15:4902–4907. doi: 10.1182/blood-2007-10-116327. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
9. Center for Disease Control, National Healthcare Safety Network. Bloodstream Infections. [(accessed on 15 December 2020)]; Available online: //www.cdc.gov/nhsn/pdfs/pscmanual/4psc_clabscurrent.pdf
10. Al-Asadi O., Almusarhed M., Eldeeb H. Predictive risk factors of venous thromboembolism (VTE) associated with peripherally inserted central catheters (PICC) in ambulant solid cancer patients: Retrospective single Centre cohort study. Thromb. J. 2019;17:2. doi: 10.1186/s12959-019-0191-y. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
11. Decousus H., Bourmaud A., Fournel P., Bertoletti L., Labruyère C., Presles E., Merah A., Laporte S., Stefani L., Piano F.D., et al. Cancer-associated thrombosis in patients with implanted ports: A prospective multicenter French cohort study (ONCOCIP) Blood. 2018;16:707–716. doi: 10.1182/blood-2018-03-837153. [PubMed] [CrossRef] [Google Scholar]
12. Hohl Moinat C., Périard D., Grueber A., Hayoz D., Magnin J.-L., André P., Kung M., Betticher D.C. Predictors of Venous Thromboembolic Events Associated with Central Venous Port Insertion in Cancer Patients. [(accessed on 22 October 2020)];J. Oncol. 2014 doi: 10.1155/2014/743181. Available online: //www.ncbi.nlm.nih.gov/pmc/articles/PMC3934091/ [PMC free article] [PubMed] [CrossRef] [Google Scholar]
13. Suleman A., Jarvis V., Hadziomerovic A., Carrier M., McDiarmid S. Implanted vascular access device related deep vein thrombosis in oncology patients: A prospective cohort study. Thromb. Res. 2019;177:117–121. doi: 10.1016/j.thromres.2019.02.033. [PubMed] [CrossRef] [Google Scholar]
14. Saber W., Moua T., Williams E.C., Verso M., Agnelli G., Couban S., Young A., Cicco M.D., Biffi R., van Rooden C.J., et al. Risk factors for catheter-related thrombosis (CRT) in cancer patients: A patient-level data (IPD) meta-analysis of clinical trials and prospective studies. J. Thromb. Haemost. 2011;9:312–319. doi: 10.1111/j.1538-7836.2010.04126.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
15. Chopra V., Anand S., Hickner A., Buist M., Rogers M.A., Saint S., Flanders S.A. Risk of venous thromboembolism associated with peripherally inserted central catheters: A systematic review and meta-analysis. Lancet. 2013;382:311–325. doi: 10.1016/S0140-6736(13)60592-9. [PubMed] [CrossRef] [Google Scholar]
16. Taxbro K., Hammarskjöld F., Thelin B., Lewin F., Hagman H., Hanberger H., Berg S. Clinical impact of peripherally inserted central catheters vs implanted port catheters in patients with cancer: An open-label, randomised, two-centre trial. Br. J. Anaesth. 2019;122:734–741. doi: 10.1016/j.bja.2019.01.038. [PubMed] [CrossRef] [Google Scholar]
17. Lebeaux D., Larroque B., Gellen-Dautremer J., Leflon-Guibout V., Dreyer C., Bialek S., Froissart A., Hentic O., Tessier C., Ruimy R., et al. Clinical Outcome After a Totally Implantable Venous Access Port-Related Infection in Cancer Patients: A Prospective Study and Review of the Literature. Medicine. 2012;91:309–318. doi: 10.1097/MD.0b013e318275ffe1. [PubMed] [CrossRef] [Google Scholar]
18. Gao Y., Liu Y., Ma X., Wei L., Chen W., Song L. The incidence and risk factors of peripherally inserted central catheter-related infection among cancer patients. Ther. Clin. Risk. Manag. 2015;11:863–871. doi: 10.2147/TCRM.S83776. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
19. Bertoglio S., Faccini B., Lalli L., Cafiero F., Bruzzi P. Peripherally inserted central catheters (PICCs) in cancer patients under chemotherapy: A prospective study on the incidence of complications and overall failures. J. Surg. Oncol. 2016;113:708–714. doi: 10.1002/jso.24220. [PubMed] [CrossRef] [Google Scholar]
20. Kang J., Chen W., Sun W., Ge R., Li H., Ma E., Su Q., Cheng F., Hong J., Zhang Y., et al. Peripherally inserted central catheter-related complications in cancer patients: A prospective study of over 50,000 catheter days. J. Vasc. Access. 2017;18:153–157. doi: 10.5301/jva.5000670. [PubMed] [CrossRef] [Google Scholar]
21. Wang T.-Y., Lee K.-D., Chen P.-T., Chen M.-C., Chen Y.-Y., Huang C.-E., Kuan F.C., Chen C.-C., Lu C.H. Incidence and risk factors for central venous access port-related infection in Chinese cancer patients. J. Formos. Med. Assoc. 2015;114:1055–1060. doi: 10.1016/j.jfma.2015.06.013. [PubMed] [CrossRef] [Google Scholar]
22. Touré A., Vanhems P., Lombard-Bohas C., Cassier P., Péré-Vergé D., Souquet J.-C., Ecochard R., Chambrier C. Totally implantable central venous access port infections in patients with digestive cancer: Incidence and risk factors. Am. J. Infect. Control. 2012;40:935–939. [PubMed] [Google Scholar]
23. Chopra V., O’Horo J.C., Rogers M.A.M., Maki D.G., Safdar N. The risk of bloodstream infection associated with peripherally inserted central catheters compared with central venous catheters in adults: A systematic review and meta-analysis. Infect. Control. Hosp. Epidemiol. 2013;34:908–918. doi: 10.1086/671737. [PubMed] [CrossRef] [Google Scholar]
24. Barbetakis N., Asteriou C., Kleontas A., Tsilikas C. Totally implantable central venous access ports. Analysis of 700 cases. J. Surg. Oncol. 2011;104:654–656. doi: 10.1002/jso.21990. [PubMed] [CrossRef] [Google Scholar]
25. Green E., Macartney G., Zwaal C., Marchand P., Kutzscher L., Savage P., Robb-Blenderman L., Volpe J., Collins L., Brouwers M. Special Article Managing central venous access devices in cancer patients: A practice guideline. [(accessed on 27 September 2020)];Can. Oncol. Nurs. J./Revue Canadienne de Soins Infirmiers en Oncologie. 2008 18 doi: 10.5737/1181912x18219. Available online: //canadianoncologynursingjournal.com/index.php/conj/article/view/244 [CrossRef] [Google Scholar]
26. Narducci F., Jean-Laurent M., Boulanger L., Bédoui S.E., Mallet Y., Houpeau J.L., Hamdani A., Penel N., Fourniera C. Totally implantable venous access port systems and risk factors for complications: A one-year prospective study in a cancer centre. Eur. J. Surg. Oncol. 2011;37:913–918. doi: 10.1016/j.ejso.2011.06.016. [PubMed] [CrossRef] [Google Scholar]
27. Kreidieh F.Y., Moukadem H.A., El Saghir N.S. Overview, prevention and management of chemotherapy extravasation. World J. Clin. Oncol. 2016;7:87–97. doi: 10.5306/wjco.v7.i1.87. [PMC free article] [PubMed] [CrossRef] [Google Scholar]